By activating both GIP and GLP-1 receptors, tirzepatide injections helps reduce appetite, control food intake, and improve blood sugar levels all while supporting safe and effective weight loss
The dose-escalation schedule for Wegovy is fixed: Weeks 1-4: 0.25 mg subcutaneously once weekly Weeks 5-8: 0.5 mg once weekly Weeks 9-12: 1.0 mg once weekly Weeks 13-16: 1.7 mg once weekly Week 17 onward: 2.4 mg once weekly (maintenance) GI side effects, including nausea, vomiting, and the delayed gastric emptying that complicates ibuprofen use, are most intense during dose escalation
New vial, new concentration, dose adjustment, anything
Combining it with other medications, supplements, or alcohol without caution can lead to unwanted side effects or reduce its effectiveness